Bayer Philippines Issues Notice and Warning to the Public Regarding Patent Infringement
Bayer Intellectual Property GmbH (Bayer IP) has issued a notice and warning to the public regarding the infringement of its patent for the prevention and treatment of thromboembolic disorders. The patent, Philippine Patent No. 1/2007/501642, was issued on March 25, 2013, and will remain valid until January 19, 2026.
The patent pertains to the use of rivaroxaban, a direct factor Xa inhibitor, in the form of a once-daily rapid-release tablet for patients in need. The authorized products under this patent are marketed and distributed by Bayer Philippines, Inc., under the brand XARELTO (10, 15, 20 mg rivaroxaban).
Bayer IP and Bayer Philippines have become aware of entities intending to distribute products that infringe upon the patent. It is illegal for any person or entity to manufacture, use, offer to sell, or sell pharmaceutical products that contain elements of the patent claims or their equivalents without obtaining consent, authorization, or a license from Bayer IP. Such acts constitute patent infringement.
Products that are not sourced from Bayer, including Bayer Philippines, are not licensed under the patent, and their safety and effectiveness cannot be guaranteed by Bayer.
Bayer IP and Bayer Philippines have warned that the use and distribution of unauthorized products constitute patent infringement and that legal action may be taken against individuals or entities engaged in such acts.
If anyone has concerns, information, or reports related to Philippine Patent No. 1/2007/501642 for Rivaroxaban (XARELTO), they are advised to contact the legal counsel of Bayer IP at the provided contact details.
